Eribulin for the treatment of metastatic breast cancer: a top of the table chemotherapy option?

Chris Twelves speaks to Roshaine Gunawardana, Commissioning Editor: Professor Twelves is Professor of Clinical Cancer Pharmacology and Oncology and heads the Section of Oncology and Cancer Research (Clinical) at the Leeds Institute of Cancer and Pathology (Leeds, UK). He is a medical oncologist with a particular interest in new drug development and clinical pharmacology; his clinical practice has been in colorectal and breast cancer. After training as an oncologist in London he was Senior Lecturer, then Reader, in Medical Oncology in Glasgow at the Beatson Oncology Centre (Glasgow, UK) before taking up his current post at the University of Leeds and Leeds Teaching Hospitals Trust (Leeds, UK). Professor Twelves is Head of the Experimental Cancer Medicine Centre at the Leeds Cancer Research UK Centre (Leeds, UK). He has been a member of the Cancer Research UK New Agents Committee and Chair of the New Drug Development Group of the European Organisation for Reasearch and Treatment of Cancer (EORTC). Professor Twelves has been involved in the development of several important new agents including capecitabine, and eribulin. Professor Twelves has published over 200 papers in journals including the New England Journal of Medicine, Lancet and Journal of Clinical Oncology and spoken at numerous international meetings. He has also edited, or contributed to, several books. He is a past Scientific Chair of the European Cancer Conference.